Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Comedian and Emmy-nominated actor Kym Whitley opens up about her long journey with weight management. The "Happy Gilmore 2" ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.